Multiple presentations will highlight the
clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) in
DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma
ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on
several of its antibody drug conjugates (ADCs), including ZYNLONTA®
(loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and
ADCT-602, will be presented at the 64th American Society of
Hematology (ASH) Annual Meeting, which will be held in New Orleans,
Louisiana from December 10-13, 2022.
Details of ADC Therapeutics’ oral presentation:
Real-World Effectiveness and Economic Impact Associated with
Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with
Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US
Abstract: 1002 Session: 905. Outcomes Research—Lymphoid
Malignancies: Health Outcomes in CAR T and Stem Cell
Transplantation Date and Session Time: Monday, December 12, 2022,
4:30–6:00 p.m. CST Presentation Time: 5:45 p.m. CST Location:
Ernest N. Morial Convention Center, 291-292 Presenter: Dai Chihara,
MD, The University of Texas MD Anderson Cancer Center
Details of an independently developed oral presentation:
ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to
PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell
Acute Lymphoblastic Leukemia: A Phase 1 Trial Abstract: 216
Session: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding
Transplantation and Cellular Immunotherapies: Clinical Trials Date
and Session Time: Saturday, December 10, 2022, 2:00–3:30 p.m. CST
Presentation Time: 3:15 p.m. CST Location: Ernest N. Morial
Convention Center, 265-268 Presenter: Nitin Jain, MD, Department of
Leukemia, The University of Texas MD Anderson Cancer Center
Details of ADC Therapeutics’ poster presentations:
CD19 Expression by IHC Alone Is Not a Predictor of Response
to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial
and Quantitative Systems Pharmacology Modeling Abstract: 4297
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological:
Poster III Date and Time: Monday, December 12, 2022, 6:00–8:00 p.m.
CST Presenter: Paolo F. Caimi, MD, Blood and Marrow Transplant
Program, Taussig Cancer Institute, Cleveland Clinic Foundation,
Cleveland, OH
A Phase 2, Open-Label Study of Loncastuximab Tesirine in
Combination with Rituximab (Lonca-R) in Previously Untreated
Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
(LOTIS-9) Abstract: 2955 Session: 626. Aggressive Lymphomas:
Prospective Therapeutic Trials: Poster II Date and Time: Sunday,
December 11, 2022, 6:00-8:00 p.m. CST Presenter: Jason Westin, MD,
Department of Lymphoma/Myeloma, The University of Texas MD Anderson
Cancer Center
Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who
Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or
Tafasitamab Plus Lenalidomide By Line of Therapy Abstract: 3598
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster II
Date and Time: Sunday, December 11, 2022, 6:00-8:00 p.m. CST
Presenter: Mehdi Hamadani, MD, Division of Hematology and Oncology,
Medical College of Wisconsin, Milwaukee, WI
Identification of Predictive Biomarkers for Response of R/R
DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass
Whole-Genome Sequencing (WGS) Abstract: 1542 Session: 621.
Lymphomas: Translational—Molecular and Genetic: Poster I Date and
Time: Saturday, December 10, 2022, 5:30-7:30 p.m. CST Presenter:
Francesco Vallania, PhD, Freenome, San Francisco, CA
Exploratory Analysis of Factors Influencing Efficacy and
Safety of Camidanlumab Tesirine: Data from the Open-Label,
Multicenter, Phase 2 Study of Patients with Relapsed or Refractory
Classical Hodgkin Lymphoma (R/R cHL) Abstract: 1594 Session:
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and
Epidemiological: Poster I Date and Time: Saturday, December 10,
2022, 5:30-7:30 p.m. CST Presenter: Alex F. Herrera, MD, Department
of Hematology and Hematopoietic Cell Transplantation, City of Hope
Comprehensive Cancer Center, Duarte, CA
CD25, Soluble CD25, and CCL17 As Potential Predictors of
Clinical Response to Camidanlumab Tesirine in Patients with
Relapsed/Refractory Classical Hodgkin Lymphoma Abstract: 4192
Session: 622. Lymphomas: Translational–Non-Genetic: Poster III Date
and Time: Monday, December 12, 2022, 6:00-8:00 p.m. CST Presenter:
Alex F. Herrera, MD, Department of Hematology and Hematopoietic
Cell Transplantation, City of Hope Comprehensive Cancer Center,
Duarte, CA
Development of Anti-CD45 Antibody Drug Conjugates As Targeted
Conditioning Agents for Transplantation/Gene Therapy with Potent
Anti-Leukemic Properties Abstract: 4584 Session: 701.
Experimental Transplantation: Basic and Translational: Poster III
Date and Time: Monday, December 12, 2022, 6:00-8:00 p.m. CST
Presenter: Jenny Yeung, PhD, UCL Great Ormond Street Institute of
Child Health and UCL Cancer Institute, London, United Kingdom
Posters will be available in the poster exhibit hall (Hall D) of
the Ernest N. Morial Convention Center on December 10 from 9:00
a.m.-7:30 p.m. CST and December 11 & 12 from 9:00 a.m.-8:00
p.m. CST. Presenters planning to attend in person are expected to
present during the final two hours of the noted viewing time.
Presentations will also be available on a virtual platform.
Presenters are subject to change.
Abstracts are available through the ASH online meeting program
and will be published in the November supplemental issue of
Blood.
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once
bound to a CD19-expressing cell, ZYNLONTA is internalized by the
cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
The potent payload binds to DNA minor groove with little
distortion, remaining less visible to DNA repair mechanisms. This
ultimately results in cell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) has approved
ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult
patients with relapsed or refractory (r/r) large B-cell lymphoma
after two or more lines of systemic therapy, including DLBCL not
otherwise specified, DLBCL arising from low-grade lymphoma and also
high-grade B-cell lymphoma. The trial included a broad spectrum of
heavily pre-treated patients (median three prior lines of therapy)
with difficult-to-treat disease, including patients who did not
respond to first-line therapy, patients refractory to all prior
lines of therapy, patients with double/triple hit genetics and
patients who had stem cell transplant and CAR-T therapy prior to
their treatment with ZYNLONTA. This indication is approved by the
FDA under accelerated approval based on overall response rate and
continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory
trial.
ZYNLONTA is also being evaluated as a therapeutic option in
combination studies in other B-cell malignancies and earlier lines
of therapy.
About Camidanlumab Tesirine (Cami)
Camidanlumab tesirine (Cami) is an antibody drug conjugate (ADC)
comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC,
licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine
(PBD) dimer payload, tesirine. Once bound to a CD25-expressing
cell, Cami is internalized into the cell where enzymes release the
PBD-based payload, killing the cell. This applies to
CD25-expressing tumor cells and also to CD25-expressing Tregs. The
intra-tumoral release of its PBD payload may also cause bystander
killing of neighboring tumor cells, and PBDs have also been shown
to induce immunogenic cell death. All of these properties of Cami
may enhance immune-mediated anti-tumor activity.
Cami is being evaluated in a pivotal Phase 2 clinical trial in
patients with relapsed or refractory Hodgkin lymphoma and a Phase
1b clinical trial as monotherapy and in combination with
pembrolizumab in solid tumors.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a pivotal Phase 2 trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221102006135/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205 Amanda Loshbaugh
ADC Therapeutics amanda.loshbaugh@adctherapeutics.com +1
917-288-7023 Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024